Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
about
Different anthracycline derivates for reducing cardiotoxicity in cancer patientsDifferent anthracycline derivates for reducing cardiotoxicity in cancer patientsDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyDifferent dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapyCardio-oncology: Concepts and practiceEvaluation and management of patients with heart disease and cancer: cardio-oncologyExpert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.Cardiac complications of chemotherapy: role of imaging.Assessing the Cardiac Toxicity of Chemotherapeutic Agents: Role of Echocardiography.Noninvasive diagnosis of chemotherapy related cardiotoxicityNon-pegylated liposomal doxorubicin in lymphoma: patterns of toxicity and outcome in a large observational trial.Nuclear imaging in detection and monitoring of cardiotoxicity.Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathyConsensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis.Deletion of LOX-1 Protects against Heart Failure Induced by Doxorubicin.Anthracycline cardiotoxicity.Early cardiac function monitoring for detection of subclinical Doxorubicin cardiotoxicity in young adult patients with breast cancer.Monitoring of anthracycline-induced cardiotoxicity.Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by Mito-QLeft ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan.Biological drugs: classic adverse effects and new clinical evidences.Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.Update on cardiotoxicity of anti-cancer treatments.Comprehensive review on cardio-oncology: Role of multimodality imaging.123 I-MIBG imaging for detection of anthracycline-induced cardiomyopathy.Role of Imaging in Cardio-Oncology.Targeted ultrasound imaging of apoptosis with annexin a5 microbubbles in acute Doxorubicin-induced cardiotoxicity.Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation.Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model.The Positive Effects of Exercise in Chemotherapy-Related Cardiomyopathy.Acute exercise protects against doxorubicin cardiotoxicity.Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart.Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity.The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients.Early anthracycline-induced cardiotoxicity monitored by echocardiographic Doppler parameters combined with serum hs-cTnT.Creatine Supplementation and Doxorubicin-Induced Skeletal Muscle Dysfunction: An Ex Vivo Investigation.Rehabilitative exercise in a rat model of doxorubicin cardiotoxicity.
P2860
Q24235507-526CECBC-655C-423D-B967-3B22867BCE23Q24236622-3386DBFA-DA4E-4D89-BD71-616356F72E0EQ24240568-5EF10DA4-6DE9-4504-A398-35831B0211EAQ24243810-B0E91098-9ED9-46F8-8D98-8D9E4201BB56Q26750878-BB8D080D-20E6-4AC7-B05A-6DAEDD5C2B02Q26998273-E2897240-3B18-42D7-94A4-138DD352A221Q30401812-B8C2E4B7-A26C-4CFC-8AF4-C5B73507EA1AQ30415201-743A8723-40FE-49A6-B5E4-FE83740E999DQ30446509-043B1CE9-226B-49B6-B0F9-C0D152F7595BQ30461444-58D84797-A11C-4232-A12F-684475D64E27Q33418655-D929C008-1ABC-4125-BCED-B88580B4197AQ33942611-9ADCDC49-B52B-4F2E-8D20-7A0AEB9AD08CQ35673260-A093C7BC-7DD2-432F-A8E0-1EA361E1EDBCQ35934224-150BEF7F-6B47-48F1-B370-F0CAAB1310A4Q36022217-F5324536-9522-4ACD-87BA-C5241A5444E4Q36624983-2FBFDDF4-3467-472C-AD42-74F115C2492AQ36998127-48F2349F-4125-41ED-994C-21E429396C69Q37038186-3CFD00EF-34B4-403F-B0EB-257F6E2897D4Q37279228-BC723407-73AD-4565-A92B-AAB50E0BC52AQ37330143-BC05ED98-753C-4F53-8178-A7608334F48BQ37342407-2F392FAC-B8E2-4DB1-8648-64C61224CC7CQ38015746-F23076F0-C179-4EA9-AB35-BD73297D16C6Q38079197-19901B6C-E35B-44D6-8CEB-9EEDE77ACBFDQ38686222-D5A9B176-DDDC-4F58-83F7-5F3145A5C0F5Q38844387-E27AF777-E81F-4A5D-B008-163B74F8E045Q39157770-59E474B9-83F5-49AC-82A4-3B152F167CD1Q39285218-AFC50746-0D93-4578-B3AD-2AEF70F1B33DQ41813615-C7436656-DBEB-493A-921C-7334CC625F09Q42706690-A4680132-36CF-49F4-8679-4A11E0ABC44FQ45754683-1A72C6D2-8C40-4959-AC02-136CF54F5A4BQ46171847-60E491A3-7D1D-450B-80E6-B9EE8E130F9FQ46269647-711ED985-2E68-4155-86F8-95B9E18510E7Q46348879-6F1950CE-9B93-470A-A7A4-34592E8C587CQ46450246-A647D557-7AE6-414D-A257-55790A49AA77Q46740080-E838D485-C1B7-49EE-80D6-72188F6C01FCQ47155288-1C1CAD03-6F7C-4405-A6D6-61960DF6AD86Q47311297-41E0A2AF-6B70-49CB-9A54-CC9767F181B0Q48299794-60E8B3E4-F636-44C7-AC23-002EF3A6402DQ50785546-7AAFDD97-9250-43D0-884C-84D194FCC946Q51277742-022BAB62-9062-43DB-BD34-8A8648FFBFFD
P2860
Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Early decline in left ventricu ...... otoxicity in lymphoma patients
@ast
Early decline in left ventricu ...... otoxicity in lymphoma patients
@en
type
label
Early decline in left ventricu ...... otoxicity in lymphoma patients
@ast
Early decline in left ventricu ...... otoxicity in lymphoma patients
@en
prefLabel
Early decline in left ventricu ...... otoxicity in lymphoma patients
@ast
Early decline in left ventricu ...... otoxicity in lymphoma patients
@en
P2093
P2860
P356
P1476
Early decline in left ventricu ...... otoxicity in lymphoma patients
@en
P2093
E Jantunen
E Vanninen
J Hartikainen
T Nousiainen
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600346
P407
P577
2002-06-01T00:00:00Z